Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers.

Details

• Alternative Title:
  The Journal of Infectious Diseases, 2025, v. 231, no. 3: Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers.
• Journal Article:
  The Journal of Infectious Diseases
• Personal Author:
  Mak, Josephine ; Khan, Sana ; Britton, Amadea ; Rose, Spencer ; Gwynn, Lisa ; Ellingson, Katherine D. ; Meece, Jennifer ; Feldstein, Leora R. ; Tyner, Harmony ; Edwards, Laura J. ; Thiese, Matthew S. ; Naleway, Allison ; Gaglani, Manjusha ; Solle, Natasha ; Burgess, Jefferey L. ; Lamberte, Julie Mayo ; Shea, Meghan ; Hunt-Smith, Taryn ; Caban-Martinez, Alberto ; Porter, Cynthia ; Wiegand, Ryan ; Rai, Ramona ; Hegmann, Kurt T. ; Hollister, James ; Fowlkes, Ashley ; Wesley, Meredith ; Philips, Andrew L. ; Rivers, Patrick ; Bloodworth, Robin ; Newes-Adeyi, Gabriella ; Olsho, Lauren E. W. ; Yoon, Sarang K. ; Saydah, Sharon ; Lutrick, Karen
• Description:
  Data are limited on whether vaccination reduces post COVID conditions (PCCs) risk after less severe nonhospitalized coronavirus disease 2019 (COVID-19). This study assessed whether COVID-19 vaccination protected against PCCs in persons with mild initial infections during Delta and Omicron variant predominance.
  
  This study utilized a case-control design, nested within the HEROES-RECOVER cohort. Participants aged ≥18 years with test-confirmed severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) between 28 June 2021 and 14 September 2022 were surveyed for PCCs, defined by symptoms lasting >4 weeks after initial infection. Cases self-reported PCCs and controls self-reported no PCCs. The exposure was messenger RNA (mRNA) COVID-19 vaccination (2 or 3 monovalent doses). Odds of PCCs among vaccinated and unvaccinated persons were compared with logistic regression.
  
  Of 936 participants, 23.6% reported PCCs and 83.2% were vaccinated. Participants who received 3 vaccine doses had lower odds of PCC-related gastrointestinal, neurological, and other symptoms compared to unvaccinated participants (adjusted odds ratio 95% confidence interval: 0.37 .16-.85, 0.56 .32-.97, and 0.48 .25-.91, respectively).
  
  COVID-19 vaccination protected against development of PCCs among persons with mild infection during both Delta and Omicron variant predominance, supporting vaccination as an important PCCs prevention tool.
• Content Notes:
  Author manuscript
• Subjects:
  • Humans
  • COVID-19
  • Male
  • Female
  • Adult
  • Middle Aged
  • COVID-19 Vaccines
  • SARS-CoV-2
  • Case-Control Studies
  • Prospective Studies
  More +
• Keywords:
  • post-COVID conditions
  • COVID-19 vaccines
  • mRNA vaccines
  • Long COVID
  • COVID-19
• Source:
  The Journal of Infectious Diseases, 2025, v. 231, no. 3
• DOI:
  https://doi.org/10.1093/infdis/jiae556
• ISSN:
  0022-1899 ; 1537-6613
• Pubmed ID:
  39531735
• Pubmed Central ID:
  PMC11913564
• Document Type:
  Text
• Funding:
  UM1 TR004409/TR/NCATS NIH HHSUnited States/ ; 75D30120R68013/CC/CDC HHSUnited States/ ; Abt Associates, Inc)/
• Genre:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  665-676 (20 pdf pages)
• Volume:
  231
• Issue:
  3
• Download URL:
  https://stacks.cdc.gov/view/cdc/261927/cdc_261927_DS1.pdf
• File Type:
  [PDF - 704.37 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:ca614016ce3d45cc7df53e677d7c8d692a99c034202f2597c134b4fef0eb09ee7e0adca9c507b22228524a5591d41b1a461c9d0c5fecb2a5c309a85033f55456